Successfully created a Moonfare account
Premium content

Get Access to the Premium Content

Enter your Name and Email and get access to premium content

E-mail Address

Already have an account? Sign in

Premium content

Confirm your Email

Please click on the link that has been just sent to [email] in order to verify your email and proceed to browse investment opportunities

Resend confirmation link
Oops! Something went wrong while submitting the form.

Apax Partners sell controlling stake in Neuraxpharm to Permira

Funds advised by Apax Partners recently announced an agreement to sell their controlling stake in Neuraxpharm – a leading European specialty pharmaceutical firm focused on the treatment of central nervous system disorder (CNS) – to funds advised by Permira.

Neuraxpharm focuses on improving the mental well-being and the quality of life of patients affected by CNS disorders throughout the European region. Its operations are active in 13 countries and cover 80% of the European CNS drug market.

Back in 2016, Apax Funds saw the opportunity to generate an European leader in CNS specialty pharmaceuticals.Following these lines, the PE investment group acquired Invent Farma in Spain and neuraxpharma Arzneimittel in Germany, leading to the foundations of the Neuraxpharm group.

  • Neuraxpharm today has annual revenues in excess of €460 million and 850 employees.

Source: Apax


Join to the Moonfare Platform

Create an Account

Already have an account? Sign in

Invest with Moonfare

Moonfare gives you access to the top 5% of funds we review. Our clients have trusted us to invest over €500 million.

Sign Up